Related Experiment Video

Updated: May 31, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Recent advances in the treatment of hypertension

Dagmara Hering1, Murray D Esler, Henry Krum

  • 1Neurovascular Hypertension and Kidney Disease Laboratory, Baker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Road Central, Melbourne, Victoria 8008, Australia.

Expert Review of Cardiovascular Therapy
|July 1, 2011
PubMed

Insights

Uncontrolled high blood pressure (hypertension) causes millions of deaths annually. New drug and device strategies are being explored to improve blood pressure control and reduce cardiovascular risks.

Area of Science:

  • Cardiovascular Medicine
  • Hypertension Research
  • Public Health

Background:

  • Uncontrolled blood pressure is a leading global cause of mortality, responsible for over 7 million deaths yearly.
  • Current lifestyle and pharmacological treatments for hypertension show unsatisfactory control rates.
  • There is a critical need for innovative strategies to manage hypertension effectively.

Purpose of the Study:

  • To review novel pharmacological and device-based approaches for hypertension management.
  • To assess the potential of new strategies in improving blood pressure control.
  • To evaluate the impact of enhanced blood pressure control on cardiovascular outcomes.

Main Methods:

  • Review of recent pharmacological advancements in hypertension treatment.
  • Analysis of emerging device-based therapies for blood pressure regulation.
  • Synthesis of data on the efficacy and safety of novel approaches.

Main Results:

  • Several novel pharmacological agents show promise in lowering blood pressure.
  • Innovative device-based interventions are demonstrating potential for improved hypertension management.
  • These new strategies may offer enhanced blood pressure control compared to existing methods.

Conclusions:

  • Novel pharmacological and device-based interventions represent a promising frontier in hypertension management.
  • These approaches have the potential to significantly improve blood pressure control rates.
  • Successful implementation could lead to better cardiovascular outcomes for patients with hypertension.

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...